To establish if CD133 expression influenced tumor-initiating property of a cancer cell, we used the pancreatic cancer cell line MIA PaCa-2 (with 0.1% endogenous CD133 expression) and overexpressed CD133. The gene discussed is PROM1; the disease is pancreatic neoplasm.